Ducks in a row microRNA play Regulus Therapeutics Inc. is hoping Verastem Inc. (NASDAQ:VSTM) didn't satiate investor appetite for preclinical biotech plays. Last week, Regulus filed to raise up to $57.5 million in an IPO,...

A U.S. team that included researchers from Regulus Therapeutics Inc. has reported the first successful inhibition of a microRNA- ^ miR-10b-in tumor cells, a feat that previously had only been accomplished in normal tissue. 1...